[SLAM family proteins as therapeutic targets in multiple myeloma].

Antibodies, Monoclonal Humans Immunotherapy Multiple Myeloma Signaling Lymphocytic Activation Molecule Family Member 1
Antibody drug conjugate Immunotherapy Multiple myeloma SLAM family molecules

Journal

[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R

Informations de publication

Date de publication:
2020
Historique:
entrez: 8 8 2020
pubmed: 8 8 2020
medline: 25 9 2020
Statut: ppublish

Résumé

Reports have described the excellent efficacies of new immunotherapeutic strategies, such as monoclonal antibody (mAb) therapies, in multiple myeloma (MM) patients. Signaling lymphocytic activation molecule family (SLAMF) molecules are expressed strongly on normal lymphocytes and plasma cells from MM patients. The anti-SLAMF7 mAb elotuzumab (ELO) has been approved for the treatment of relapsed/refractory MM (RRMM). In MM patients, a high serum soluble SLAMF7 (sSLAMF7) concentration is associated with aggressive clinical characteristics. This suggests a proliferative function of the SLAMF7-sSLAMF7 interaction that could be inhibited by ELO. SLAMF3 is also expressed strongly and constitutively on myeloma cells. We observed the aggressive characteristics of SLAMF3

Identifiants

DOI: 10.11406/rinketsu.61.818 PMID: 32759570
pubmed: 32759570
doi: 10.11406/rinketsu.61.818
doi:

Substances chimiques

Antibodies, Monoclonal 0
Signaling Lymphocytic Activation Molecule Family Member 1 169535-43-7

Types de publication

Journal Article

Langues

jpn

Sous-ensembles de citation

IM

Pagination

818-826

Auteurs

Hideto Tamura (H)

Department of Hematology, Nippon Medical School.

Mariko Ishibashi (M)

Department of Microbiology and Immunology, Nippon Medical School.

Hidemi Takahashi (H)

Department of Microbiology and Immunology, Nippon Medical School.

Koiti Inokuchi (K)

Department of Hematology, Nippon Medical School.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › [SLAM family proteins as therapeutic targets...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [SLAM family proteins as therapeutic targets...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › [SLAM family proteins as therapeutic targets...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › [SLAM family proteins as therapeutic targets...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Famille des molécules de signalisation de l'activation des lymphocytes › Membre-1 de la famille des molécules de signalisation de l'activation des lymphocytes › [SLAM family proteins as therapeutic targets...